

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangxi Rimag Group Co., Ltd.
江西一脉阳光集团股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2522)

PROFIT WARNING

This announcement is made by Jiangxi Rimag Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited management accounts of the Group for the year ended December 31, 2024 and the information currently available to the Board, it is expected that the Group will record for the year ended December 31, 2024 (“**FY2024**”) a net loss ranging from approximately RMB55.0 million to RMB60.0 million, as compared to a net profit of approximately RMB36.6 million for the year ended December 31, 2023 (“**FY2023**”).

The Board believes that the aforementioned change in profit/loss from FY2023 to FY2024 is mainly due to (i) the macroeconomic environment and the slowdown in demand from various medical institutions which has led to a slowdown in the relevant bidding process, resulting in, among others, (a) the delivery of certain imaging solutions by the Group pursuant to agreements entered into in 2024 be postponed to 2025; and (b) the commencement of operation of certain newly established imaging centers of the Group be postponed to 2025, which resulted in a decrease in revenue of the Group for FY2024 as compared to FY2023; and (ii) the incurrence of certain expenses in FY2024 in connection with the Company's listing on The Stock Exchange of Hong Kong Limited in 2024.

As at the date of this announcement, the Company is still in the process of finalizing the annual results of the Group for FY2024. The information contained in this announcement is only based on the preliminary assessment made by the management of the Company with reference to the unaudited management accounts of the Group for FY2024 and the information currently available to the Board, and these information have not been audited or reviewed by the auditor or the audit committee of the Company. The actual financial results of the Group for FY2024 may differ from those as disclosed in this announcement. In accordance with the Listing Rules, the Group's annual results announcement for FY2024 is expected to be published on or before March 31, 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
Mr. CHEN Zhaoyang
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, March 18, 2025

As at the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. LIU Senlin and Mr. GUO Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.